ABCG2 and non-small cell lung carcinoma: Next, we examined the expression of MDR markers, specifically ABCB1, ABCC1, and ABCG2, in NSCLC cultures after treatment with afatinib, alectinib, ceritinib, crizotinib, dabrafenib, erlotinib, gefitinib, nintedanib, osimertinib, and trametinib.